Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 19 Stomach Neoplasms 12 Colorectal Neoplasms 10 Carcinoma, Non-Small-Cell Lung 7 Rectal Neoplasms 6 Esophageal Squamous Cell Carcinoma 5 Pancreatic Neoplasms 4 Esophageal Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Neoplasm Metastasis 3 Nasopharyngeal Carcinoma 3 Lung Neoplasms 3 Triple Negative Breast Neoplasms 2 Endometrial Neoplasms 2 Turcot syndrome 1 Thyroid Neoplasms 1 Squamous Cell Non-small Cell Lung Cancer 1 Spinocerebellar Degenerations 1 Sarcoma 1 Salivary Gland Malignant Neoplasms 1 Resectable NSCLC 1 Recurrence 1 Rare Tumor 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplasms 1 NSCLC 1 Microsatellite Stable Metastatic Colorectal Cancer 1 Metastatic Gastroesophageal Junction Adenocarcinoma 1

Interventions

Drug Therapy 4 Pemetrexed 3 Carboplatin 3 osimertinib 2 Radiotherapy 2 toripalimab 1 tislelizumab 1 sugemalimab 1 spartalizumab 1 sintilimab 1 pembrolizumab 1 cemiplimab 1 aflutinib 1 Vinorelbine 1 Radiosurgery 1 Platinum 1 Paclitaxel 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Chemotherapy, Adjuvant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × NSCLC × sintilimab × Clear all

NCT06479759 2024-06-28

ACCLAIM

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡